

## Special Issue

# Cellular Therapies for Treating High Risk Haematological Neoplasm

### Message from the Guest Editors

The availability of CAR-T therapy is changing the treatment landscape of several haematological malignancies and redefining the role of both allogeneic and autologous stem cell transplants. With this Special Issue on haematology, we aim to collect manuscripts from real world experiences regarding the management of patients affected with haematological malignancies and candidates for both transplants or CAR-T strategies. The ultimate goal of this Special Issue is to capture the modification of the role of transplant strategies as a consequence of the availabilities of advanced immune effector cells therapies and also of a better understanding of the mechanisms of the pathogenesis of each disease.

---

### Guest Editors

Dr. Daniele Avenoso

King's College Hospital, London, UK

Dr. Maurizio Miglino

Dipartimento di Medicina Interna e Specialità Mediche - DIMI,  
Università Degli Studi di Genova, Genoa, Italy

---

### Deadline for manuscript submissions

closed (15 April 2024)



# Hematology Reports

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.2  
CiteScore 1.4  
Indexed in PubMed



[mdpi.com/si/170839](https://mdpi.com/si/170839)

*Hematology Reports*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
hematolrep@mdpi.com

[mdpi.com/journal/  
hematolrep](https://mdpi.com/journal/hematolrep)





# Hematology Reports

an Open Access Journal  
by MDPI

Impact Factor 1.2  
CiteScore 1.4  
Indexed in PubMed



[mdpi.com/journal/  
hematolrep](http://mdpi.com/journal/hematolrep)

## About the Journal

### Message from the Editor-in-Chief

*Hematology Reports* (ISSN 2038-8330) is an international open access journal on all aspects of prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials.

---

### Editor-in-Chief

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.4 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the second half of 2025).

